Stock Price Quote

ASTRAZENECA PHARMA INDIA LTD.

NSE : ASTRAZENBSE : 506820ISIN CODE : INE203A01020Industry : Pharmaceuticals & DrugsHouse : Astrazeneca Pharma India - MNC
BSE5497.151.25 (+0.02 %)
PREV CLOSE ( ) 5495.90
OPEN PRICE ( ) 5599.95
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 352
TODAY'S LOW / HIGH ( )5472.60 5599.95
52 WK LOW / HIGH ( )3102 7208
NSE5507.756.55 (+0.12 %)
PREV CLOSE( ) 5501.20
OPEN PRICE ( ) 5519.40
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 5372
TODAY'S LOW / HIGH( ) 5478.15 5539.80
52 WK LOW / HIGH ( )3098 7220.95
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 11-07 1979
Management Info
Narayan K Seshadri - Chairman Sanjeev Kumar Panchal - Managing Director
Registered Office

Address Block N1, 12th Floor,Manyata Embassy Business Park,Rachenahalli, Outer Ring Road,
Bengaluru,
Karnataka-560045

Phone 080 6774 8000

Email comp.secy@astrazeneca.com

Website www.astrazenecaindia.com/india

Registrars Details
Integrated Registrary Management Services Pvt Ltd.-(Formerly Integrated Enterprises (India) Ltd)
30, Ramana Residency,4th Cross, Sampige Road,Malleswaram,Bangalore
Listing : BSE, NSE, MCX

NEWS

20Feb AstraZeneca Pharma India informs about
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Re..
20Jan Astrazeneca Pharma India informs about
Astrazeneca Pharma India has informed that AstraZeneca Pharma India has..
20Jan AstraZeneca Pharma gets nod to import
AstraZeneca Pharma India has received permission to import pharmaceutica..
21Dec Mazagon Dock Shipbuilders, Deepak Nitr
Mazagon Dock Shipbuilders (MDL) has signed a contract with Acquisition w..
21Dec AstraZeneca Pharma to launch Trastuzum
AstraZeneca Pharma India is planning to launch Trastuzumab deruxtecan 10..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit158992.929999999999
Gross Profit 203.98 1341.05
Operating Profit 247.161914.27
Net Sales 3057.8910029.71

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Dr. Reddy's Lab (BSE)
peergroup  6445.00 (1.27%)
M.Cap ( in Cr)107511.08
Orchid Pharma (BSE)
peergroup  1217.20 (5.76%)
M.Cap ( in Cr)6173.53
Lincoln Pharma (BSE)
peergroup  737.20 (8.43%)
M.Cap ( in Cr)1476.59
Concord Biotech (BSE)
peergroup  1474.60 (2.39%)
M.Cap ( in Cr)15426.71
Mercury Laboratories (BSE)
peergroup  919.70 (3.87%)
M.Cap ( in Cr)110.36

Shareholding Pattern

PROMOTERS 75%
MUTUAL FUNDS/UTI 2.75%
NON-INSTITUTION 19.58%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Astrazeneca Pharma India Ltd.

Astrazeneca Pharma India Ltd. was incorporated in the year 1979. Its today's share price is 5497.15. Its current market capitalisation stands at Rs 13742.88 Cr. In the latest quarter, company has reported Gross Sales of Rs. 10076.1 Cr and Total Income of Rs.10290.7 Cr. The company's management includes Bhavana Agrawal, Sylvia Lorena Varela Ramon, Hooi-Bien Chuah, Manasa R, Ankush Nandra, Sanjeev Kumar Panchal, Shilpa Shridhar Divekar, Revathy Ashok, Narayan K Seshadri.

It is listed on the BSE with a BSE Code of 506820 , NSE with an NSE Symbol of ASTRAZEN and ISIN of INE203A01020. It's Registered office is at Block N1, 12th Floor,Manyata Embassy Business Park,Rachenahalli, Outer Ring RoadBengaluru-560045, Karnataka. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are AF Ferguson & Co, Bharat S Raut & Co, BSR & Co, BSR & Co LLP, Price Waterhouse & Co, Price Waterhouse & Co Chartered Accountants LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.